
IXHL
Healthcare · Drug Manufacturers - Specialty & Generic · $24.7M market cap
$1.97-0.05 (-2.5%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +10.6% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | -0.66 | -0.15 | +77.3% |
| Sep 25, 2026 | Before the open | 0.13 | -0.14 | -207.7% |
| May 15, 2026 | Before the open | -0.84 | -0.49 | +41.7% |
| Feb 13, 2026 | Before the open | -0.93 | -0.85 | +8.6% |
| Nov 14, 2025 | Before the open | -18.09 | -0.92 | +94.9% |
| Sep 29, 2025 | After the close | -0.45 | -0.78 | -73.3% |
| May 15, 2025 | Before the open | -0.46 | -0.24 | +47.8% |
| Feb 14, 2025 | Before the open | -20.43 | -15.56 | +23.8% |
| Nov 14, 2024 | After the close | -21.48 | -13.41 | +37.6% |
| Feb 26, 2024 | Before the open | — | -0.33 | — |
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin…